H.C. Wainwright downgraded Marinus Pharmaceuticals (MRNS) to Neutral from Buy with a price target of $2, down from $11. The firm is “disappointed” after Marinus reported that ganaxolone failed in its pivotal trial to treat refractory TSC-associated seizures. This is the second significant setback for Marinus this year following the miss in refractory status epilepticus earlier in the spring, the analyst tells investors in a research note.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRNS:
- Marinus Pharmaceuticals downgraded to Hold from Buy at TD Cowen
- Marinus Pharmaceuticals downgraded to Hold from Buy at Jefferies
- Marinus Pharmaceuticals price target lowered to $3 from $23 at EF Hutton
- Marinus Pharmaceuticals price target lowered to 50c from $2 at Baird
- Marinus Pharmaceuticals downgraded to Market Perform at JMP Securities